The European Medicines Agency has issued several recommendations to help facilitate and improve the use of patient registry data to support the evaluation of chimeric antigen receptor T-cell (CAR T-cell) therapies.
The recommendations, which include introducing a method for the systematic collection of a set of core commonly-defined data elements, follow...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?